Inverseon, CBio Combine Programs in All-Stock Merger
Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane.
The merged entity will combine programs from each company to focus broadly on inflammatory disease.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST